Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Humans also lack the ability to produce the Galα1–3Galβ1–4GlcNAc–R epitope, which is common in murine cells, and this has been shown to induce anaphylaxis [8,33].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003;Chung et al., 2008;Macher and Galili, 2008;Padler-Karavani et al., 2008;Ghaderi et al., 2012).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Chung et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“However, anti-α-Gal IgE antibodies can cause allergic reactions, such as anaphylaxis, against cetuximab, a therapeutic monoclonal antibody targeting epidermal growth factor receptor (EGFR)”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Chung et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
(1945) · Harvard University Press eBooks · doi:10.4159/harvard.9780674184220 · Cited by 1,078
The diagnosis and management of anaphylaxis: An updated practice parameter
LIEBERMAN, P., KEMP, S., OPPENHEIMER, J., LANG, D., BERNSTEIN, I., NICKLAS, R., ANDERSON, J., BERNSTEIN, D., BERNSTEIN, J., & FINK, J. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 667
Symposium on the Definition and Management of Anaphylaxis: Summary report
Sampson, H. A., Muñoz-Furlong, A., Bock, S. A., Schmitt, C., Bass, R., Chowdhury, B. A., Decker, W. W., Furlong, T. J., Galli, S. J., Golden, D. B., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 641
The incidence and management of infusion reactions to infliximab: a large center experience
Cheifetz, A. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00231-4 · Cited by 491
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Macher, B. A., & Galili, U. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2007.11.003 · Cited by 404
O'Neil, B. H., Allen, R., Spigel, D. R., Stinchcombe, T. E., Moore, D. T., Berlin, J. D., & Goldberg, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7812 · Cited by 358
Self-citationThe α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy
Galili, U. (2005) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2005.01366.x · Cited by 336
Chapman, M. D., Aalberse, R. C., Brown, M. J., & Platts-Mills, T. A. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.3.812 · Cited by 297
Self-citationQian, J., Liu, T., Yang, L., Daus, A., Crowley, R., & Zhou, Q. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.01.023 · Cited by 291
Self-citationPoor biologic activity of cross-reactive IgE directed to carbohydrate determinants of glycoproteins
van der Veen, M. J., van Ree, R., Aalberse, R. C., Akkerdaas, J., Koppelman, S. J., Jansen, H. M., & van der Zee, J. S. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70245-8 · Cited by 287
Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer
Cook-Bruns, N. (2001) · Oncology · doi:10.1159/000055403 · Cited by 158
Florvaag, E., Johansson, S. G. O., Öman, H., Venemalm, L., Degerbeck, F., Dybendal, T., & Lundberg, M. (2005) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2004.00591.x · Cited by 158
Monoclonal antibodies, immunogenicity, and associated infusion reactions.
Cheifetz, A. S., & Mayer, L. (2005) · PubMed · Cited by 152
Monoclonal antibodies to the major feline allergen Fel d I
de Groot, H., van Swieten, P., van Leeuwen, J., Lind, P., & Aalberse, R. C. (1988) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(88)90079-6 · Cited by 129
The Role of Indoor Allergen Sensitization and Exposure in Causing Morbidity in Women with Asthma
Lewis, S. A., Weiss, S. T., Platts-Mills, T. A. E., Burge, H., & Gold, D. R. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.7.2103044 · Cited by 101
Self-citationErwin, E. A., Custis, N. J., Satinover, S. M., Perzanowski, M. S., Woodfolk, J. A., Crane, J., Wickens, K. L., & Platts‐Mills, T. A. E. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.12.1131 · Cited by 100
Self-citationABO blood group and related antigens, natural antibodies and transplantation
Milland, J., & Sandrin, M. S. (2006) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00721.x · Cited by 90
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody
Needle, M. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70091-2 · Cited by 84
Functionally important glycosyltransferase gain and loss during catarrhine primate emergence
Koike, C., Uddin, M., Wildman, D. E., Gray, E. A., Trucco, M., Starzl, T. E., & Goodman, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610012104 · Cited by 82
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody
Needle, M. N. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.35648 · Cited by 70
Cat IgA, representative of new carbohydrate cross-reactive allergens
Adédoyin, J., Grönlund, H., Öman, H., Johansson, S. G. O., & van Hage, M. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.11.637 · Cited by 64
Decreased vasopressin responsiveness in vasodilatory septic shock–like conditions*
Léone, M., & Boyle, W. A. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000206466.56669.be · Cited by 63
Septic Shock — Vasopressin, Norepinephrine, and Urgency
Parrillo, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejme0800245 · Cited by 58
High prevalence of IgE antibodies among blood donors in Sweden and Norway
Johansson, S. G. O., Nopp, A., Florvaag, E., Lundahl, J., Söderström, T., Guttormsen, A. B., Hervig, T., Lundberg, M., Öman, H., & van Hage, M. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00896.x · Cited by 48
Glycosylation of human IgG antibodies: Relevance to therapeutic applications
Jefferis, R. (2002) · Cited by 39
Definition of immunogenic carbohydrate epitopes.
Paschinger, K., Fabini, G., Schuster, D. M., Rendić, D., & Wilson, I. B. H. (2005) · Acta Biochimica Polonica · doi:10.18388/abp.2005_3422 · Cited by 31
Prevalence and titer of IgE antibodies to mouse allergens
Platts‐Mills, T. A. E., Satinover, S. M., Naccara, L. M., Litonjua, A. A., Phipatanakul, W., Carter, M. C., Heymann, P. W., Woodfolk, J. A., Peters, E. J., & Gold, D. R. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.06.032 · Cited by 21
Self-citationCommins, S. P., Lucas, S., Hosen, J., Satinover, S. M., Borish, L., & Platts‐Mills, T. A. E. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.12.103 · Cited by 9
Self-citation[Evaluation of the analytical performance of the ImmunoCap 250 (Sweden Diagnostics)].
Cavalier, E., Carlisi, A., & Chapelle, J.-P. (2006) · PubMed · Cited by 3
Research works printed but not linked: 1
- Carolina; association with atopic history. J Clin Oncol 2007;25:3644-8.
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
Human milk oligosaccharides: Every baby needs a sugar mama
Bode, L. (2012) · Glycobiology · doi:10.1093/glycob/cws074 · Cited by 1,809
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Drug Allergy: An Updated Practice Parameter
(2010) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2010.08.002 · Cited by 957
Metadata
- Authors
- Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., Slebos, R. J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D. J., & Platts-Mills, T. A. E.
- Affiliations
- Vanderbilt University (US)
- Bristol-Myers Squibb (United States) (US)
- Stanford University (US)
- Duke Medical Center (US)
- University of Virginia (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-13
- Volume
- 358
- Issue
- 11
- Pages
- 1109-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2361129
- OpenAlex
- W2140035322
- Cited by
- 1,521
- References
- 35
- Citations by year
- 2026: 63 · 2025: 79 · 2024: 64 · 2023: 83 · 2022: 78 · 2021: 78 · 2020: 94 · 2019: 80 · 2018: 78 · 2017: 109 · 2016: 90 · 2015: 99 · 2014: 88 · 2013: 97 · 2012: 94
- FWCI
- 57.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- Bristol-Myers Squibb
- Vanderbilt University
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- National Institutes of Health (20565, 2r01ai020565-29, 5r01ca118582-05, AI-20565)
- U.S. Public Health Service (AI-AADCRC-U19-070364)
- National Cancer Institute (R01-CA-118582, P50CA095103, P50CA95103)
- National Institute of Allergy and Infectious Diseases (AI 20565, R01AI035796, R01AI-020565, AI/EHS-35796, R29AI035796, R37AI020565)
- National Institute of Dental and Craniofacial Research (R01DE017982)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- cetuximab, anaphylaxis, drug hypersensitivity, IgE antibodies, galactose-alpha-1,3-galactose, Fab fragment, monoclonal antibodies, epidermal growth factor receptor, pre-existing antibodies, colorectal cancer, head and neck squamous cell carcinoma
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Anaphylaxis, Antibodies, Monoclonal, Epitopes, Antineoplastic Agents, Cross Reactions, Disaccharides, Female, Humans, Immunoglobulin E, Male, Middle Aged, Protein Binding, Protein Conformation, Case-Control Studies, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.